

해외 바이오의약품 임상 현황 ('23년 7월 3주)

한국바이오의약품협회, 2023.07.25.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.07.17.~2023.07.23.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05945485	A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults	Biological: DCVC H1 HA mRNA vaccine Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine Other: Sodium Chloride, 0.9%	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05945485
NCT05877508	Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)	Drug: AER002 Other: Placebo	Michael Peluso, MD Aerium Therapeutics University of California, San Francisco	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05877508
NCT05819892	Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer	Drug: Paclitaxel Drug: Carboplatin Drug: Dostarlimab Drug: Cisplatin	M.D. Anderson Cancer Center GlaxoSmithKline	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05819892
NCT05727384	Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study	Drug: Clazakizumab Drug: Placebo	Anne B. Newman CSL Behring University of Pittsburgh	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05727384
NCT05478837	Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma	Drug: Cyclophosphamide Drug: Fludarabine Biological: Autologous Anti-H3.3K27M TCR-expressing T-cells	University of California, San Francisco The V Foundation Parker Institute for Cancer Immunotherapy Alliance for Cancer Gene Therapy	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05478837
NCT05453396	Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies	Biological: Loncastuximab Tesirine	University of Washington	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05453396
NCT05010564	Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)	Genetic: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy	Baylor College of Medicine Texas Children's Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05010564
NCT05356897	Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	Biological: Trastuzumab Drug: Trifluridine and Tipiracil Hydrochloride Drug: Tucatinib	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05356897
NCT05903339	Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV	Drug: V3G CH848 Pr-NP1 60mcg Drug: 3M-052-AF 5mcg Drug: Alum 500 mcg Drug: V3G CH848 mRNA-Tr2 50mcg Drug: ACU-026-001-1 2.0mg Drug: V3G CH848 Pr-NP1 100mcg	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05903339
NCT05936151	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	Drug: LY3437943 Drug: Placebo	Eli Lilly and Company	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05936151

해외 바이오의약품 임상 현황 ('23년 7월 3주)

한국바이오의약품협회, 2023.07.25.

○ 중국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05954429	A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study	Drug: serplulimab Drug: Fruquintinib	Junjie Peng Fudan University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05954429
NCT05940116	A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors	Drug: HS-20117	Hansoh BioMedical R&D Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05940116
NCT05940064	Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma	Drug: Zanubrutinib, Polatuzumab Vedotin, Rituximab	Peng Liu Shanghai Zhongshan Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05940064
NCT05940051	Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Zanubrutinib, Polatuzumab vedotin and Rituximab	Peng Liu Shanghai Zhongshan Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05940051
NCT05917782	A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects	Biological: Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL) Biological: Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL) Biological: Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)	Suzhou Connect Biopharmaceuticals, Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05917782
NCT05866354	To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies	Drug: Tisotumab Vedotin	Zai Lab (Shanghai) Co., Ltd. Zai Lab (Hong Kong), Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05866354